公开(公告)号：US20220315661A1

公开(公告)日：2022-10-06

申请号：US17609359

申请日：2020-05-11

Applicant: GENMAB B.V.

Inventor： Ulf FORSSMANN ,  Manish GUPTA ,  Jens Thing MORTENSEN ,  Merete ELLEKILDE-PEDERSEN ,  Marije Berber OVERDIJK ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/573 ,  A61P35/02

Abstract: The present invention relates to a combination of two antibody molecules that bind to human DR5 antigen and their use in treating cancer. In particular, the present invention relates to dosage regimens for such anti-DR5 antibodies comprising administering to subject weekly dosages followed by biweekly dosages, or one or two priming dosage(s) followed by biweekly dosages.

公开(公告)号：US10882913B2

公开(公告)日：2021-01-05

申请号：US16451714

申请日：2019-06-25

Applicant: GENMAB B.V.

Inventor： Marije Overdijk ,  Kristin Strumane ,  Rik Rademaker ,  Esther Breij ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/30 ,  C12N15/10 ,  A61P35/00 ,  C12N15/62 ,  A61K39/00 ,  C07K16/46 ,  A61K38/00

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20150337049A1

公开(公告)日：2015-11-26

申请号：US14760157

申请日：2014-01-09

Applicant: GENMAB B.V.

Inventor： Aran Frank LABRIJN ,  Joyce MEESTERS ,  Joost J. NEIJSSEN ,  Edward Norbert VAN DEN BRINK ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/28

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Abstract translation: 本文描述的是在第一和第二多肽链中的至少一个中包含氨基酸取代的蛋白质。 此外，描述了与所述蛋白质相关的用途和方法。

公开(公告)号：US20250145720A1

公开(公告)日：2025-05-08

申请号：US18744540

申请日：2024-06-14

Applicant: GENMAB B.V.

Inventor： Paul PARREN ,  Frank BEURSKENS ,  Rob N. DE JONG ,  Sandra VERPLOEGEN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  C07K16/00 ,  C07K16/36 ,  C07K16/40 ,  C07K19/00

Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

公开(公告)号：US12247080B2

公开(公告)日：2025-03-11

申请号：US17108373

申请日：2020-12-01

Applicant: GENMAB B.V.

Inventor： Marije Overdijk ,  Kristin Strumane ,  Rik Rademaker ,  Esther Breij ,  Janine Schuurman ,  Paul Parren

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N15/62 ,  A61K38/00 ,  A61K39/00 ,  C07K14/715 ,  C07K16/46

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US12173076B2

公开(公告)日：2024-12-24

申请号：US16482747

申请日：2018-02-12

Applicant: GENMAB B.V.

Inventor： Frank Beurskens ,  Marije Overdijk ,  Annieck M. Diks ,  Rob De Jong ,  Kristin Strumane ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/10

Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

公开(公告)号：US20230212301A1

公开(公告)日：2023-07-06

申请号：US18055362

申请日：2022-11-14

Applicant: Genmab B.V.

Inventor： Andreea Ioan ,  Frank Beurskens ,  Rob N. de Jong ,  Janine Schuurman ,  Esther C. W. Breij ,  Isil Altintas ,  Pauline L. de Goeje ,  David Satijn ,  Peter Boross ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Kristina Schödel

IPC: C07K16/28 ,  C07K16/42 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/4208 ,  A61K2039/505

Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20210230301A1

公开(公告)日：2021-07-29

申请号：US17012102

申请日：2020-09-04

Applicant: GENMAB B.V.

Inventor： Rob N. DE JONG ,  Frank BEURSKENS ,  Paul PARREN ,  Aran Frank LABRIJN ,  Janine SCHUURMAN ,  Arjen VLUG ,  Sandra VERPLOEGEN

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10 ,  C07K16/36 ,  C07K16/00 ,  C07K16/32 ,  C07K16/12

Abstract: The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

公开(公告)号：US20200332016A1

公开(公告)日：2020-10-22

申请号：US16841306

申请日：2020-04-06

Applicant: GENMAB B.V.

Inventor： Claudine Brigitte Fernande Vermot-Desroches ,  Olivier Frédéric Subiger ,  Laurence Françoise Jeanne-Marie Bourdin

IPC: C07K16/28

Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.

公开(公告)号：US10647774B2

公开(公告)日：2020-05-12

申请号：US15436583

申请日：2017-02-17

Applicant: GENMAB B.V.

Inventor： Claudine Brigitte Fernande Vermot-Desroches ,  Olivier Frédéric Subiger ,  Laurence Françoise Jeanne-Marie Bourdin

IPC: C12N15/13 ,  C12N5/10 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.